- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00723203
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
A Phase II Study of LBH589, a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients With Acute Leukemia (AL) or in Newly Diagnosed Patients Over the Age of 60
RATIONALE: Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying the side effects of panobinostat and to see how well it works in treating patients with relapsed or refractory acute lymphoblastic leukemia or acute myeloid leukemia.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
OBJECTIVES:
Primary
- To determine the antitumor activity of panobinostat, in terms of objective response rate, time to progression, and survival, in patients with relapsed or refractory acute lymphoblastic leukemia or acute myeloid leukemia.
- To assess the toxicity of panobinostat in these patients.
Secondary
- To perform correlative laboratory studies to assess changes in various proteins that may be altered by histone deacetylase inhibition therapy.
OUTLINE: Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo peripheral blood and bone marrow sample collection at baseline and on day 28 of course 1 for correlative laboratory studies. Samples are analyzed by RT-PCR for reactivation of FANCG, FOXO3A, GADD45A, GADD45B, GADD45G, H2AX, and TP73.
After completion of study treatment, patients are followed for at least 4 weeks.
PROJECTED ACCRUAL: A total of 74 patients (37 with acute myeloid leukemia and 37 with acute lymphoblastic leukemia) will be accrued for this study.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
California
-
Duarte, California, Vereinigte Staaten, 91010-3000
- City of Hope Comprehensive Cancer Center
-
Pasadena, California, Vereinigte Staaten, 91030
- South Pasadena Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed acute myeloid leukemia or acute lymphoblastic leukemia (ALL)
- Relapsed or refractory disease
- Patients with Philadelphia chromosome-positive (Ph+) ALL refractory to BCR/ABL inhibitors are eligible
- Patients who have relapsed after prior autologous or allogenic stem cell transplant are eligible
- No active CNS disease
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Serum albumin ≥ 3 g/dL
- AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5.0 times ULN if transaminase elevation is due to leukemic involvement)
- Bilirubin ≤ 1.5 times ULN
- Creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 50 mL/min
- Potassium ≥ lower limit of normal (LLN)
- Phosphorous ≥ LLN
- Serum total calcium (corrected for serum albumin) or serum ionized calcium ≥ LLN
- Magnesium ≥ LLN
- Thyroid stimulating hormone and free T4 normal (thyroid hormone replacement therapy allowed)
- LVEF ≥ LLN by MUGA or ECHO
No impaired cardiac function, including any of the following:
- QTc > 450 msec
- Congenital long QT syndrome
- History of sustained ventricular tachycardia
- History of ventricular fibrillation or torsades de pointes
Bradycardia (i.e., heart rate < 50 beats per minute)
- Pacemaker allowed provided heart rate ≥ 50 beats per minute
- Myocardial infarction or unstable angina within the past 6 months
- New York Heart Association class III-IV congestive heart failure
- Right bundle branch block and left anterior hemiblock (bifascicular block)
- No uncontrolled hypertension
- No unresolved diarrhea > CTCAE grade 1
- No impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral panobinostat
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective double-barrier contraception during and for 3 months after completion of study treatment
- No other primary malignancy within the past 5 years, other than curatively treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin
- No HIV or hepatitis C positivity
- No other concurrent severe and/or uncontrolled medical condition
- No significant history of non-compliance to medical regimens or inability to give reliable informed consent
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from all prior therapy
- More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy
- More than 4 weeks since prior valproic acid
- No other prior treatment with a histone deacetylase inhibitor
- No concurrent medication that may cause QTc prolongation or induce torsades de pointes
- No concurrent CYP3A4 inhibitors
- No concurrent grapefruit, grapefruit juice, or Seville (sour) oranges
- No concurrent radiotherapy
- No other concurrent anticancer therapy or investigational therapy
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Treatment (panobinostat)
Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. panobinostat: 40 mg Monday, Wednesday and Friday of every week in a 28 day cycle |
40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
Day 1 and day 28 samples
Day 1 and day 28 samples
Day 1 and day 28 samples
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Hematological Response Rate
Zeitfenster: Up to 6 cycles of treatment, up to 24 weeks.
|
Morphologic CR: morphologic leukemia-free state with absolute neutrophil count > 1000/uL and platelet count ≥ 100,000/uL and independent of blood transfusions.
Cytogenic CR: morphologic CR along with reversion to a normal karyotype by cytogenetic analysis.
Molecular CR: morphologic CR with no residual disease by molecular or flow cytometric detection methods.
Morphologic CR with incomplete blood recovery (CRi): morphologic CR except for residual neutropenia (<1000/uL) and/or thrombocytopenia (<1000,000/uL).
PR: same hematologic values for a CR but with a decrease of at least 50% in percentage of blasts to a post-treatment value of 5% to 25% in bone marrow aspirate.
(If the pre-treatment blast percentage was 50-100% this must decrease to a value between 5-25%.
If the pre-treatment blast percentage was 20-49% this must decrease by at least half to a value > 5%.)
A value ≤ 5% is also considered a PR if Auer rods are present.
Hematological response = morphologic CR+PR.
|
Up to 6 cycles of treatment, up to 24 weeks.
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Leslie Popplewell, MD, City of Hope Comprehensive Cancer Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Lymphoproliferative Erkrankungen
- Lymphatische Erkrankungen
- Immunproliferative Erkrankungen
- Leukämie, lymphatisch
- Leukämie
- Vorläuferzelle lymphoblastische Leukämie-Lymphom
- Molekulare Mechanismen der pharmakologischen Wirkung
- Enzym-Inhibitoren
- Antineoplastische Mittel
- Histon-Deacetylase-Inhibitoren
- Panobinostat
Andere Studien-ID-Nummern
- 07174
- P30CA033572 (US NIH Stipendium/Vertrag)
- CHNMC-07174
- NOVARTIS-CHNMC-07174
- CDR0000601203 (Registrierungskennung: NCI PDQ)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Leukämie
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... und andere MitarbeiterUnbekanntAllogene hämatopoetische Stammzelltransplantation | Bedingungen | Mixed-Lineage-Leukemia (MLL)-Rearranged Acute LeukemiaChina
-
Shenzhen Second People's HospitalRekrutierungLeukämie | Myeloisch | Chronisch | BCR-ABL (Breakpoint Cluster Region-Abelson Murine Leukemia) | PositivChina
Klinische Studien zur panobinostat
-
University of Wisconsin, MadisonNovartis PharmaceuticalsBeendetNeuroendokrine TumorenVereinigte Staaten
-
Novartis PharmaceuticalsAbgeschlossenAkute myeloische Leukämie | Refraktäre LeukämieBelgien, Korea, Republik von, Truthahn, Deutschland, Australien, Frankreich, Schweiz, Vereinigtes Königreich, Spanien, Italien, Peru, Vereinigte Staaten
-
Novartis PharmaceuticalsAbgeschlossenFortgeschrittene solide TumorenSchweiz, Niederlande, Vereinigte Staaten, Vereinigtes Königreich
-
Translational Research in OncologyBeendet
-
Centre Leon BerardAbgeschlossen
-
Novartis PharmaceuticalsAbgeschlossenProstatakrebsKanada, Vereinigte Staaten
-
Medical University of South CarolinaNovartis PharmaceuticalsAbgeschlossenWeichteilsarkom | Nierenkrebs | Nicht-kleinzelliger Lungenkrebs (NSCLC)Vereinigte Staaten
-
Singapore General HospitalAbgeschlossenAngioimmunoblastisches T-Zell-Lymphom | Hepatosplenales T-Zell-Lymphom | Peripheres T-Zell-Lymphom (nicht anders angegeben) | Extranodales NK/T-Zell-Lymphom vom nasalen Typ | Enteropathie – Typ T-Zell-Lymphom | Anaplastisches großzelliges Lymphom (ALCL) (ALK-1 negativ) | Rezidiviertes ALCL (ALK-1-positiv)...Singapur, Malaysia, Korea, Republik von
-
Tulane University Health Sciences CenterNovartis; Board of Regents, State of LouisianaZurückgezogenBrustkrebsVereinigte Staaten
-
Cheng-Chia (Fred) WuFocused Ultrasound FoundationAktiv, nicht rekrutierendDiffuses intrinsisches Pontin-Gliom | Diffuses Mittelliniengliom, H3 K27M-Mutante | Diffuse pontine und thalamische GliomeVereinigte Staaten